|
The Efficacy and Safety of UGN-102 as a Chemoablation Agent in Patients With LG NMIBC at Intermediate Risk of Recurrence
NCT ID : 03558503
Protocol Number : TC-BC-12
Phase : 2
|
Urology and Urologic Oncology
|
Linehan
|
|
The OLYMPUS Study – Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)
NCT ID : 02793128
Protocol Number : TC-UT-03
Phase : 3
|
Urology and Urologic Oncology
|
Linehan
|
|
An Observational Study of Memantine XR (extended release) and Pregabalin Combination Therapy in Chemotherapy-Induced Peripheral Neuropathy (CIPN)
NCT ID : 03709888
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)
NCT ID : 03131960
Phase : 3
|
Brain Tumors & Neuroscience
|
Achrol
|
|
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT ID : 03553836
Protocol Number : MK-3475-716
Phase : 3
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (INTACT)
NCT ID : 03393000
Phase : 3
|
|
Kesari
|
|
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
NCT ID : 03515538
Phase : 2a
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Feasibility Study of the Nativis Voyager System in Patients With Newly-Diagnosed Glioblastoma Multiforme (GBM)
NCT ID : 03276268
Phase : Feasibility
|
Brain Tumors & Neuroscience
|
Barkhoudarian
|
|
A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma
NCT ID : 03463265
Phase : 2
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)
NCT ID : 03397394
Phase : 2
|
Urology and Urologic Oncology
|
Twardowski
|
|
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
NCT ID : 03633110
Phase : 1 and 2
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Twardowski
|
|
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT ID : 03425643
Phase : IIB or IIIA
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Onugha
|
|
Phase I Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Pembrolizumab in Subjects with Advanced Melanoma
NCT ID : 02565992
Protocol Number : VLA-011 (20160939)
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Phase Ib Study of Intratumoral CAVATAK(TM) (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma
NCT ID : 02307149
Protocol Number : VLA-013 (20150760)
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinoma
NCT ID : 02793128
Protocol Number : TC-UT-03 (20162686)
Phase : III
|
Urology and Urologic Oncology
|
Linehan
|
|
Phase 1B, Multicenter, Open-Label Study Of Marizomib Combined with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma
NCT ID : 02903069
Protocol Number : MRZ-112 (20161905)
Phase : Ib
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Lung Cancer in Patients Undergoing Diagnostic or Therapeutic Bronchoscopy or Thoracic Surgery
NCT ID : 02715102
Protocol Number : PROTOCOL-006 (00016248)
Phase : N/A
|
Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Mckenna, JR.
|
|
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR Study)
NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : III
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Single-Center, Open-Label, Randomized, Phase II Study of NovoTTF-200A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas
NCT ID : 02507232
Protocol Number : JWCI-16-1101 (20162693)
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Feasibility Study of the Nativis Voyager(TM) System in Patients with Recurrent Glioblastoma Multiforme (GBM)
NCT ID : 02296580
Protocol Number : NAT-101 (20141455)
Phase : Pilot/ Feasibility
|
Brain Tumors & Neuroscience
|
Barkhoudarian
|
|
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
NCT ID : 3425643
Protocol Number : MK-3475-671
Phase : III
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
O'Day
|
|
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS = 50%) (KEYNOTE-598)
NCT ID : 3302234
Protocol Number : MK 3475-598
Phase : III
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Onugha
|
|
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Camette-Guerin (BCG) Therapy
NCT ID : 02625961
Protocol Number : MK-3475-057 (20160487)
Phase : II
|
Urology and Urologic Oncology
|
Wilson
|
|
A Phase I/II Study to assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma
NCT ID : 02130466
Protocol Number : MK-3475-022 (20162631)
Phase : I/II
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)
NCT ID : 02089685
Protocol Number : MK-3475-029 (20140404)
Phase : I/II
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
An Open-Label Non-Randomized, Multicenter Phase 2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Glioblastoma at First Recurrence or Progression
NCT ID : 02858895
Protocol Number : MDNA55-05
Phase : II
|
Brain Tumors & Neuroscience
|
Achrol
|
|
Metastatic Melanoma to the Brain: Genetic, Epigenetic & Immunologic Correlation to Quality of Life and Overall Success
Protocol Number : DHDK-MEL-0512 (20120757)
Phase : N/A
|
|
Kelly
|
|
Evaluation of a Mobile Digital Solution (CancerLife) for Cancer Care and Research: A Feasibility Study
NCT ID : 03094741
Protocol Number : JWCI-17-0301
Phase : N/A
|
|
Saria
|
|
Integrating Family Caregiver Support into Cancer Clinical Trials
NCT ID : 03069287
Protocol Number : JWCI-17-0102
Phase : N/A
|
|
Saria
|
|
A Longitudinal Assessment of Tumor Evolution in Patients with Brain Cancer
NCT ID : 3425292
Protocol Number : JWCI-17-0801
Phase : N/A
|
Brain Tumors & Neuroscience
|
Kesari
|
|
An Exploratory Study of Caregiver Burden Among Family Caregivers of Cancer Patients
NCT ID : 03069105
Protocol Number : JWCI-16-1201
Phase : N/A
|
|
Saria
|
|
A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer
NCT ID : 02423525
Protocol Number : 1200-229 (20161975)
Phase : I
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors
NCT ID : 02646748
Protocol Number : INCB39110-107 (20160236)
Phase : Ib
|
Gynecologic Oncology Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
O'Day
|
|
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination with Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
NCT ID : 3347123
Protocol Number : INCB 24360-208
Phase : I/II
|
Gastrointestinal and Hepatobiliary Tumors Gynecologic Oncology Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
O'Day
|
|
A Prospective, Randomized, Blinded, Placebo-Controlled, Phase IIB Trial Of An Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs. Unloaded YCWP + DC in Stage III and Stage IV (Resected) Melanoma To Prevent Recurrence
NCT ID : 02301611
Protocol Number : Elios BB IND16101 (20141932)
Phase : II
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
NCT ID : 3397394
Protocol Number : CO-338-085
Phase : II
|
Urology and Urologic Oncology
|
Twardowski
|
|
Using Virtual Reality (VR) Models for Preoperative Planning
NCT ID : 03334344
Protocol Number : VR Models
Phase : N/A
|
Urology and Urologic Oncology
|
Linehan
|
|
A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
NCT ID : NCT03149003
Protocol Number : BBI-DSP7888-201G
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Multicenter, Open-Label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects with Advanced Melanoma Failing Front-Line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-Line Chemotherapy for Metastatic Disease
NCT ID : 02981303
Protocol Number : BT-CL-PGG-MEL/BCA-1621/MK3475 PN-545 (20162506)
Phase : II
|
Breast Surgery and Oncology Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Evaluation of the TR(ACE)® Assay for the Ability to Aid in Monitoring Disease Progress, Response to Therapy or for the Recurrent or Residual Disease for Patients with Previously Diagnosed Cancers (Stage III and IV Lung)
NCT ID : 02934360
Protocol Number : BIODYN-15-003 (20161978)
Phase : N/A
|
Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Onugha
|
|
Recombinant Human Arginase 1 (RhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety And PK/PD
NCT ID : 2285101
Protocol Number : BCT-100-005
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Prospective Multicenter Cohort Study Comparing Extent of Tumor Resection Between Microscopic Transsphenoidal Surgery and Fully Endoscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas
NCT ID : 02357498
Protocol Number : KELD-TRANSSPHER-110514 (20150524)
Phase : N/A
|
Brain Tumors & Neuroscience
|
Kelly
|
|
A Phase Ib/3, Multicenter, Open-Label Trial of Talimogene Laherparepvec in Combination with Pembrolizumab (MK-3475) for Treatment of Unresected, Stage IIIb to IVM1c Melanoma
NCT ID : 02263508
Protocol Number : 20110265 (20140931)
Phase : Ib/III
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
